Hazte socio de la SAMFyC

Última publicación SAMFyC: Actualización en MF y APS

 

AULA VIRTUAL SAMFyC

Aula de formación virtual de SAMFyC

SAMFyC CONGRESOS

Historico de Comunicaciones
presentadas a los Congresos
Andaluces de MFyC (SAMFyC), desde 2008.


* * * * * * * * * * * * * * * * * * * * * * * * *

Información Socios

Ofertas de Trabajo
Ofertas de Trabajo SOCIOS SAMFYC

¡Actualiza tus datos!
Actualiza tus datos

 

Buscador de Contenidos

Sociedades Federadas

Medicina Familiar y Comunitaria

Sociedades Científicas de Medicina Familiar y Comunitaria

Enlaces de Interés

Consulte Nuestros Enlaces.
Enlaces de Interés

Acceso Socios



Buscador de publicaciones externas y alertas bibliográficas

Abril 2014 PDF Imprimir E-mail
Lunes, 05 de Mayo de 2014 00:00

<< Volver

SELECCIÓN DE REFERENCIAS BIBLIOGRÁFICAS DE LO PUBLICADO EN RELACIÓN CON ATENCIÓN PRIMARIA

Selección realizada por Antonio Manteca González
 
 
Benbassat J. Role modeling in medical education: the importance of a reflective imitation. Acad Med 2014;89:550-554 [AO,I]
24556777             R/C
MODELO DE ROLES EN LA FORMACIÓN MÉDICA: IMPORTANCIA DE LA IMITACIÓN ESPECULAR
 
Epner DE, Baile WF. Difficult conversations: teaching medical oncology trainees communication skills one hour at a time. Acad Med 2014;89:578-584 [T,II]
24556763             R/C
CONVERSACIONES DIFÍCILES: ENSEÑAR HABILIDADES DE COMUNICACIÓN A LOS RESIDENTES DE ONCOLOGÍA MÉDICA UNA HORA CADA VEZ
 
Schweller M, Costa FO, Antônio MÂ, Amaral EM, de Carvalho-Filho MA. The impact of simulated medical consultations on the empathy levels of students at one medical school. Acad Med 2014;89:632-637 [QE,I]
24556779             R/C
IMPACTO DE LAS CONSULTAS MÉDICAS SIMULADAS SOBRE LOS NIVELES DE EMPATÍA DE LOS ESTUDIANTES EN UNA FACULTAD DE MEDICINA
 
Kesselheim JC, Sun P, Woolf AD, London WB, Boyer D. Balancing education and service in graduate medical education: data from pediatric trainees and program directors. Acad Med 2014;89:652-657 [T,I]
24556769             R/C
EQUILIBRAR FORMACIÓN Y SERVICIO EN LA FORMACIÓN MÉDICA POSTGRADUADA: DATOS DE LOS RESIDENTES DE PEDIATRÍA Y DE LOS DIRECTORES DE PROGRAMA
 
 
Tamblyn R, Eguale T, Huang A, Winslade N, Doran P. The incidence and determinants of primary nonadherence with prescribed medication in primary care: a cohort study. Ann Intern Med 2014;160:441-450 [S,I]
24687067             R/C
INCIDENCIA DE LOS DETERMINANTES DE LA FALTA DE ADHERENCIA PRIMARIA A LA MEDICACIÓN PRESCRITA EN ATENCIÓN PRINARIA: ESTUDIO DE COHORTE
 
Gudzune KA, Monroe AK, Sharma R, Ranasinghe PD, Chelladurai Y, Robinson KA. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review. Ann Intern Med 2014;160:468-476 [M,II]
24514899             R/C
EFECTIVIDAD DE LA TERAPIA COMBINADA CON ESTATINA Y OTRO AGENTE MODIFICADOR DE LOS LÍPIDOS COMPARADA CON MONOTERAPIA INTENSIFICADA CON ESTATINA: REVISIÓN SISTEMÁTICA
 
Wright JT Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison Himmelfarb CR. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med 2014;160:499-503 [AO,I]
24424788            
EVIDENCIA EN APOYO DEL OBJETIVO DE PRESION ARTERIAL SISTÓLICA DE MENOS DE 150 MM HG EN PACIENTES DE 60 AÑOS O MÁS: PUNTO DE VISTA DE LA MINORÍA
 
Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in prevalence and control of diabetes in the United States, 1988-1994 and 1999-2010. Ann Intern Med 2014;160:517-525 [S,II]
24733192             R/C
TENDENCIAS EN LA PREVALENCIA Y CONTROL DE LA DIABETES EN ESTADOS UNIDOS, 1988-1994 Y 1999-2010
 
Bannuru RR, Flavin NE, Vaysbrot E, Harvey W, McAlindon T. High-energy extracorporeal shock-wave therapy for treating chronic calcific tendinitis of the shoulder: a systematic review. Ann Intern Med 2014;160:542-549 [M,II]
24733195             R/C
TERAPIA CON ONDAS DE CHOQUE EXTRACORPÓREAS DE ALTA ENERGÍA PARA TRATAR LA TENDINITIS CRÓNICA CALCIFICADA DEL HOMBRO: REVISIÓN SISTEMÁTICA
 
McTaggart MP, Newall RG, Hirst JA, Bankhead CR, Lamb EJ, Roberts NW, et al. Diagnostic accuracy of point-of-care tests for detecting albuminuria: a systematic review and meta-analysis. Ann Intern Med 2014;160:550-557 [M,II]
24733196             R/C
EXACTITUD DIAGNÓSTICA DE LOS ANÁLISIS EN CONSULTA PARA DETECTAR ALBUMINURIA: REVISIÓN SISTEMÁTICA Y METAANÁLISIS
 
Moyer VA; U.S. Preventive Services Task Force. Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;160:558-564 [M,II]
24566474             R/C
SUPLEMENTOS DE VITAMINAS, MINERALES Y MULTIVITAMINAS PARA LA PREVENCIÓN PRIMARIA DE LA ENFERMEDAD CARDIOVASCULAR Y EL CÁNCER: DECLARACIÓN DE RECOMENDACIÓN DEL USPSTF
 
Middelbeek RJ, Abrahamson MJ. Diabetes, prediabetes, and glycemic control in the United States: challenges and opportunities. Ann Intern Med 2014;160:572-573 [AO,I]
DIABETES, PREDIABETES Y CONTROL GLUCÉMICO EN LOS ESTADOS UNIDOS: RETOS Y OPORTUNIDADES
 
 
Rieger-Reyes C, García-Tirado FJ, Rubio-Galán FJ, Marín-Trigo JM. Classification of chronic obstructive pulmonary disease severity according to the New Global Initiative for Chronic Obstructive Lung Disease 2011 Guidelines: COPD assessment test versus modified Medical Research Council Scale. Arch Bronconeumol 2014;50:129-134 [T,II]
24268434             R/C
CLASIFICACIÓN DE LA GRAVEDAD DE LA EPOC DE ACUERDO CON LAS GUÍAS GOLD 2011: PRUEBA DE VALORACIÓN DE LA EPOC FRENTE A LA ESCALA MODIFICADA DEL MEDICAL RESEARCH COUNCIL
 
 
Llor C. Medicamentos que matan y crimen organizado. Aten Primaria 2014;46:176-178 [AO,II]
MEDICAMENTOS QUE MATAN Y CRIMEN ORGANIZADO
 
Villar I, Carrillo R, Regí M, Marzo M, Arcusa N, Segundo M. Factores relacionados con la calidad de vida de los pacientes con enfermedad pulmonar obstructiva crónica. Aten Primaria 2014;46:179-187 [T,I]
24262284             R/C
FACTORES RELACIONADOS CON LA CALIDAD DE VIDA DE LOS PACIENTES CON ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA
 
Sánchez-Henarejos A, Fernández-Alemán JL, Toval A, Hernández-Hernández I, Sánchez-García AB, Carrillo JM. Guía de buenas prácticas de seguridad informática en el tratamiento de datos de salud para el personal sanitario en atención primaria. Aten Primaria 2014;46:214-222 [R,II]
24582808             R/C
GUÍA DE BUENAS PRÁCTICAS DE SEGURIDAD INFORMÁTICA EN EL TRATAMIENTO DE DATOS DE SALUD PARA EL PERSONAL SANITARIO EN ATENCIÓN PRIMARIA
 
 
Williams RP, Oakeshott P. Diagnosis and management of chronic heart failure. BMJ 2014;348:g1429 [R,I]
DIAGNÓSTICO Y MANEJO DE LA INSUFICIENCIA CARDIACA CRÓNICA
 
Handley AJ. Basic life support. BMJ 2014;348:g1730 [R,I]
SOPORTE VITAL BÁSICO
 
Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams C, Chowdhury S, Kiefte-de-Jong JC, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ 2014;348:g1903 [M,II]
24690623             R/C
VITAMINA D Y RIESGO DE MUERTE POR CAUSA ESPECÍFICA: REVISIÓN SISTEMÁTICA Y METAANÁLISIS DE ESTUDIOS DE COHORTES OBSERVACIONALES Y DE INTERVENCIONES ALEATORIZADAS
 
Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 2014;348:g2035 [M,II]
24690624             R/C
VITAMINA D Y RESULTADOS DE SALUD MÚLTIPLES: REVISIÓN PARAGUAS DE REVISIONES SISTEMÁTICAS Y METAANÁLISIS DE ESTUDIOS OBSERVACIONALES Y ENSAYOS ALEATORIZADOS
 
Sung V, Hiscock H, Tang ML, Mensah FK, Nation ML, Satzke C, et al. Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. BMJ 2014;348:g2107 [EC,I]
                               R/C
TRATAR EL CÓLICO INFANTIL CON EL PROBIÓTICO LACTOBACILLUS REUTERI: ENSAYO ALEATORIZADO DOBLE CIEGO CONTROLADO CON PLACEBO
 
Steinberg BA, Piccini JP. Anticoagulation in atrial fibrillation. BMJ 2014;348:g2116 [R,II]
24733535             R/C
ANTICOAGULACIÓN EN LA FIBRILACIÓN AURICULAR
 
Veale D, Roberts A. Obsessive-compulsive disorder. BMJ 2014;348:g2183 [R,I]
TRASTORNO OBSESIVO-COMPULSIVO
 
Moore CL, Bomann S, Daniels B, Luty S, Molinaro A, Singh D, et al. Derivation and validation of a clinical prediction rule for uncomplicated ureteral stone--the STONE score: retrospective and prospective observational cohort studies. BMJ 2014;348:g2191 [S,II]
24671981             R/C
CÁLCULO Y VALIDACIÓN DE UNA REGLA DE PREDICCIÓN CLÍNICA PARA EL CÁLCULO URETERAL NO COMPLICADO--PUNTUACIÓN STONE: ESTUDIOS DE COHORTE OBSERVACIONALES RETROSPECTIVOS Y PROSPECTIVOS
 
Henderson M, Madan I, Hotopf M. Work and mental health in the UK. BMJ 2014;348:g2256 [AO,I]
TRABAJO Y SALUD MENTAL EN EL RU
 
Micha R, Khatibzadeh S, Shi P, Fahimi S, Lim S, Andrews KG, et al; Global Burden of Diseases Nutrition and Chronic Diseases Expert Group (NutriCoDE). Global, regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a systematic analysis including 266 country-specific nutrition surveys. BMJ 2014;348:g2272 [M,II]
24736206             R/C
NIVELES DE CONSUMO NACIONALES, REGIONALES Y MUNDIALES DE GRASAS Y ACEITES EN LA DIETA EN 1990 Y 2010: ANÁLISIS SISTEMÁTICO INCLUYENDO 266 ENCUESTAS NUTRICIONALES ESPECÍFICAS POR PAÍS
 
Pringsheim T, Becker WJ. Triptans for symptomatic treatment of migraine headache. BMJ 2014;348:g2285 [R,I]
TRIPTANES EN EL TRATAMIENTO SINTOMÁTICO DE LA MIGRAÑA
 
Carlsson S, Assel M, Sjoberg D, Ulmert D, Hugosson J, Lilja H, et al. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ 2014;348:g2296 [S,II]
24682399             R/C
INFLUENCIA DE LOS NIVELES DE PSA EN SANGRE A LOS 60 AÑOS SOBRE LOS BENEFICIOS Y PERJUICIOS DEL CRIBAJE DE CÁNCER DE PRÓSTATA: ESTUDIO DE COHORTE POBLACIONAL
 
Welsh P, Sattar N. Vitamin D and chronic disease prevention. BMJ 2014;348:g2280 [AO,I]
VITAMINA D Y PREVENCIÓN DE LA ENFERMEDAD CRÓNICA
 
Bennett WE Jr. Probiotics and infant colic. BMJ 2014;348:g2286 [AO,I]
PROBIÓTICOS Y CÓLICO INFANTIL
 
Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC. Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ 2014;348:g2301 [M,II]
24735917             R/C
HIPERTENSIÓN CRÓNICA Y RESULTADOS EN EL EMBARAZO: REVISIÓN SISTEMÁTICA Y METAANÁLISIS
 
Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014;348:g2366 [M,II]
24736555             R/C
TRATAMIENTO CON INCRETINAS Y RIESGO DE PANCREATITIS EN PACIENTES CON DIABETES MELLITUS TIPO 2: REVISIÓN SISTEMÁTICA Y METAANÁLISIS DE ESTUDIOS ALEATORIZADOS Y NO ALEATORIZADOS
 
Freemantle N, Shallcross LJ, Kyte D, Rader T, Calvert MJ. Oseltamivir: the real world data. BMJ 2014;348:g2371 [R,I]
OSELTAMIVIR: LOS DATOS DEL MUNDO REAL
 
Price A, Beard D. Arthroscopy for degenerate meniscal tears of the knee. BMJ 2014;348:g2382 [AO,I]
ARTROSCOPIA PARA LOS DESGARROS MENISCALES DEGENERATIVOS DE LA RODILLA
 
Isaacs D, McVernon J. Introducing a new group B meningococcus vaccine. BMJ 2014;348:g2415 [AO,I]
INTRODUCCIÓN DE UN NUEVO GRUPO DE VACUNA PARA EL MENINGOCOCO B
 
Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ 2014;348:g2467 [M,II]
                               R/C
EFECTO DE LA SIGMOIDOSCOPIA DE CRIBAJE Y LA COLONOSCOPIA DE CRIBAJE SOBRE LA INCIDENCIA Y MORTALIDAD DE CÁNCER COLORRECTAL: REVISIÓN SISTEMÁTICA Y METAANÁLISIS DE ENSAYOS ALEATORIZADOS CONTROLADOS Y ESTUDIOS OBSERVACIONALES
 
Jefferson T, Jones M, Doshi P, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2545 [M,II]
                               R/C
OSELTAMIVIR PARA LA GRIPE EN ADULTOS Y NIÑOS: REVISIÓN SISTEMÁTICA DE INFORMES DE ESTUDIOS CLÍNICOS Y RESUMEN DE LOS COMENTARIOS REGULATORIOS
 
Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.
BMJ 2014;348:g2547 [M,II]
                               R/C
ZANAMIVIR PARA LA GRIPE EN ADULTOS Y NIÑOS: REVISIÓN SISTEMÁTICA DE INFORMES DE ESTUDIOS CLÍNICOS Y RESUMEN DE LOS COMENTARIOS REGULATORIOS
 
Krumholz HM, Hines HH Jr. Neuraminidase inhibitors for influenza. BMJ 2014;348:g2548
INHIBIDORES DE LA NEURAMINIDASA PARA LA GRIPE
 
Wilt TJ, Dahm P. PSA screening for prostate cancer. BMJ 2014;348:g2559 [AO,I]
CRIBAJE CON PSA PARA EL CÁNCER DE PRÓSTATA
 
Stansby G, Avital L, Jones K, Marsden G; Guideline Development Group. Prevention and management of pressure ulcers in primary and secondary care: summary of NICE guidance. BMJ 2014;348:g2592 [M,II]
PREVENCIÓN Y MANEJO DE LAS ÚLCERAS POR PRESIÓN EN ATENCIÓN PRIMARIA Y SECUNDARIA: RESUMEN DE LA GUÍA NICE
 
Bhutta ZA. Antibiotics to promote growth in children? BMJ 2014;348:g2624 [AO,I]
¿ANTIBIÓTICOS PARA PROMOVER EL CRECIMIENTO EN NIÑOS?
 
Loder E, Tovey D, Godlee F. The Tamiflu trials. BMJ 2014;348:g2630 [AO,I]
LOS ENSAYOS DEL TAMIFLU
 
Chapple IL. Time to take periodontitis seriously. BMJ 2014;348:g2645 [AO,I]
HORA DE TOMAR LA PERIODONTITIS EN SERIO
 
Clausen TD, Bergholt T. Chronic hypertension during pregnancy. BMJ 2014;348:g2655 [AO,I]
HIPERTENSIÓN CRÓNICA DURANTE EL EMBARAZO
 
Montori VM. The safety of incretin based drugs. BMJ 2014;348:g2779 [AO,I]
SEGURIDAD DE LOS FÁRMACOS A BASE DE INCRETINAS
 
Faillie JL, Azoulay L, Patenaude V, Hillaire-Buys D, Suissa S. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ 2014;348:g2780 [S,II]
24764569             R/C
FÁRMACOS BASADOS EN INCRETINAS Y RIESGO DE PANCREATITIS AGUDA EN PACIENTES CON DIABETES TIPO 2: ESTUDIO DE COHORTE
 
Kilpatrick ES, Atkin SL. Using haemoglobin A1c to diagnose type 2 diabetes or to identify people at high risk of diabetes. BMJ 2014;348:g2867 [R,I]
USO DE LA HbA1C PARA DIAGNOSTICAR LA DIABETES TIPO 2 O PARA IDENTIFICAR PERSONAS CON ALTO RIESGO DE DIABETES
 
Jain A. Doctors and politics. BMJ 2014;348:g2901 [AO,I]
LOS MÉDICOS Y LA POLÍTICA
 
Pipis M, Dehabadi M, Matthews E, Gould L. Tremor. BMJ 2013;347:f7200 [R,I]
TEMBLOR
 
 
Rüsch N, Thornicroft G. Does stigma impair prevention of mental disorders? Br J Psychiatry. 2014 Apr;204:249-51. doi: 10.1192/bjp.bp.113.131961. Br J Psychiatry 2014;204:249-251 [AO,I]
24692749             R/C
¿MEJORA EL ESTIGMA LA PREVENCIÓN DE LOS TRASTORNOS MENTALES?
 
Cook CC. Suicide and religion. Br J Psychiatry 2014;204:254-255 [AO,I]
24692751             R/C
SUICIDIO Y RELIGIÓN
 
Kleiman EM1, Liu RT. Prospective prediction of suicide in a nationally representative sample: religious service attendance as a protective factor. Br J Psychiatry 2014;204:262-266 [S,I]
24115346             R/C
PREDICCIÓN PROSPECTIVA DEL SUICIDIO EN UNA MUESTRA NACIONALMENTE REPRESENTATIVA: ASISTENCIA A LOS SERVICIOS RELIGIOSOS COMO FACTOR PROTECTOR
 
Dougall N, Lambert P, Maxwell M, Dawson A, Sinnott R, McCafferty S, et al. Deaths by suicide and their relationship with general and psychiatric hospital discharge: 30-year record linkage study. Br J Psychiatry 2014;204:267-273 [T,II]
24482439             R/C
MUERTES POR SUICIDIO Y SU RELACIÓN CON EL ALTA HOSPITALARIA TANTO GENERAL COMO PSIQUIÁTRICA: ESTUDIO DE ENLACE DE REGISTROS A LO LARGO DE 30 AÑOS
 
 
Frank C. Deprescribing: a new word to guide medication review. CMAJ 2014;186:407-408 [AO,I]
DEPRESCRIBIR: UNA NUEVA PALABRA PARA GUIAR LA REVISIÓN DE MEDICAMENTOS
 
Su VY, Liu CJ, Wang HK, Wu LA, Chang SC, Perng DW, et al. Sleep apnea and risk of pneumonia: a nationwide population-based study. CMAJ 2014;186:415-421 [S,II]
24591276             R/C
APNEA DEL SUEÑO Y RIESGO DE NEUMONÍA: ESTUDIO POBLACIONAL DE ÁMBITO NACIONAL
 
Bazinet RP, Chu MW. Omega-6 polyunsaturated fatty acids: Is a broad cholesterol-lowering health claim appropriate? CMAJ 2014;186:434-439 [R,I]
ÁCIDOS GRASOS POLIINSATURADOS OMEGA-6: ¿ES APROPIADA UNA AMPLIA PROCLAMA DE SALUD DE QUE BAJAN EL COLESTEROL?
 
Parmar J, Jette N, Brémault-Phillips S, Holroyd-Leduc J. Supporting people who care for older family members. CMAJ 2014;186:487-488 [AO,I]
APOYAR A LAS PERSONAS QUE CUIDAN DE MIEMBROS MAYORES DE SU FAMILIA
 
Anagnostou E, Zwaigenbaum L, Szatmari P, Fombonne E, Fernandez BA, Woodbury-Smith M, et al. Autism spectrum disorder: advances in evidence-based practice. CMAJ 2014;186:509-519 [R,I]
TRASTORNO DEL ESPECTRO DEL AUTISMO: AVANCES EN LA PRÁCTICA BASADA EN LA EVIDENCIA
 
Stiell IG, Clement CM, Aaron SD, Rowe BH, Perry JJ, Brison RJ, et al. Clinical characteristics associated with adverse events in patients with exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. CMAJ 2014;186:E193-E204 [S,II]
24549125             R/C
CARACTERÍSTICAS CLÍNICAS ASOCIADAS CON ACONTECIMIENTOS ADVERSOS EN PACIENTES CON EXACERBACIÓN DE LA EPOC: ESTUDIO PROSPECTIVO DE COHORTE
 
 
Dlott JS, George RA, Huang X, Odeh M, Kaufman HW, Ansell J, et al. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation 2014;129:1407-1414 [T,II]
24493817             R/C
VALORACIÓN NACIONAL DE LA TERAPIA ANTICOAGULANTE CON WARFARINA PARA LA PREVENCIÓN DEL ICTUS EN LA FIBRILACIÓN AURICULAR
 
Papademetriou V, Rashidi AA, Tsioufis C, Doumas M. Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions. Circulation 2014;129:1440-1451 [R,I]
ABLACIÓN DEL NERVIO RENAL EN LA HIPERTENSIÓN RESISTENTE: CÓMO HEMOS LLEGADO AQUÍ, ESTADO PRESENTE Y DIRECCIONES FUTURAS
 
Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Murray CJ, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the global burden of disease 2010 study. Circulation 2014;129:1483-1492 [T,II]
24573352             R/C
TENDENCIAS TEMPORALES EN LA MORTALIDAD POR ENFERMEDAD CARDIACA ISQUÉMICA EN 21 REGIONES DEL MUNDO, 1980 A 2010: ESTUDIO DE CARGA MUNDIAL DE ENFERMEDAD
 
Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Flaxman A, et al. The global burden of ischemic heart disease in 1990 and 2010: the global burden of disease 2010 study. Circulation 2014;129:1493-1501 [T,II]
24573351             R/C
CARGA MUNDIAL DE ENFERMEDAD ISQUÉMICA CARDIACA EN 1990 Y 2010: ESTUDIO DE CARGA MUNDIAL DE ENFERMEDAD 2010
 
Abrams DJ, Macrae CA. Long QT syndrome. Circulation 2014;129:1524-1529 [R,I]
SÍNDROME DE QT LARGO
 
Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P, et al; RE-LY Atrial Fibrillation Registry Investigators. Variations in cause and management of atrial fibrillation in a prospective registry of 15 400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation 2014;129:1568-1576 [T,II]
24463370             R/C
VARIACIONES EN LA CAUSA Y EL MANEJO DE FIBRILACIÓN AURICULAR EN UN REGISTRO PROSPECTIVO DE 15.400 PACIENTES DE URGENCIAS EN 46 PAÍSES: REGISTRO DE FIBRILACIÓN AURICULAR RE-LY
 
Lamberts M, Gislason GH, Lip GY, Lassen JF, Olesen JB, Mikkelsen AP, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 2014;129:1577-1585 [S,II]
24470482             R/C
TERAPIA ANTIPLAQUETARIA PARA LA ENFERMEDAD ARTERIAL CORONARIA ESTABLE EN PACIENTES CON FIBRILACIÓN AURICULAR QUE TOMAN UN ANTICOAGULANTE ORAL: ESTUDIO DE COHORTE DE ÁMBITO NACIONAL
 
Weitz JI, Healey JS, Skanes AC, Verma A. Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation. Circulation 2014;129:1688-1694 [R,I]
MANEJO PERIPROCEDIMENTAL DE LOS NUEVOS ANTICOAGULANTES ORALES EN PACIENTES QUE SE SOMETEN A ABLACIÓN PARA LA FIBRILACIÓN AURICULAR
 
 
Simó R, Sundstrom JM, Antonetti DA. Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care 2014;37:893-899 [R,I]
24652720             R/C
TERAPIA OCULAR ANTI-VEGF PARA LA RETINOPATÍA DIABÉTICA: EL PAPEL DEL VEGF EN LA PATOGÉNESIS DE LA RETINOPATÍA DIABÉTICA
 
Cheung N, Wong IY, Wong TY. Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications. Diabetes Care 2014;37:900-905 [R,I]
24652721             R/C
TERAPIA OCULAR ANTI-VEGF PARA LA RETINOPATÍA DIABÉTICA: RESUMEN DE SU EFICACIA CLÍNICA Y SUS APLICACIONES EN DESARROLLO
 
Cefalu WT. A "spoonful of sugar" and the realities of diabetes prevention! Diabetes Care 2014;37:906-908 [AO,I]
¡UNA "CUCHARADA DE AZÚCAR" Y LAS REALIDADES DE LA PREVENCIÓN DE LA DIABETES!
 
Sullivan SD, Jablonski KA, Florez JC, Dabelea D, Franks PW, Dagogo-Jack S, et al; Diabetes Prevention Program Research Group. Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes mellitus. Diabetes Care 2014;37:909-911 [EC,I]
24271189             R/C
RIESGO GENÉTICO DE PROGRESIÓN HACIA DIABETES TIPO 2 Y RESPUESTA A LOS CAMBIOS INTENSIVOS DE ESTILO DE VIDA O A LA METFORMINA EN MUJERES PREDIABÉTICAS CON O SIN HISTORIA DE DIABETES MELLITUS GESTACIONAL
 
Garvey WT, Ryan DH, Henry R, Bohannon NJ, Toplak H, Schwiers M, et aL. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care 2014;37:912-921 [EC,I]
24103901             R/C
PREVENCIÓN DE DIABETES TIPO 2 EN SUJETOS CON PREDIABETES Y SÍNDROME METABÓLICO TRATADOS CON FENTERMINA Y TOPIRAMATO DE LIBERACIÓN PROLONGADA
 
Dunkley AJ, Bodicoat DH, Greaves CJ, Russell C, Yates T, Davies MJ, et al. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis. Diabetes Care 2014;37:922-933 [M,II]
24652723             R/C
PREVENCIÓN DE LA DIABETES EN EL MUNDO REAL: EFECTIVIDAD DE INTERVENCIONES PRAGMÁTICAS SOBRE EL ESTILO DE VIDA PARA LA PREVENCIÓN DE DIABETES TIPO 2 Y DEL IMPACTO DEL SEGUIMIENTO DE LAS RECOMENDACIONES DE LAS GUÍAS: REVISIÓN SISTEMÁTICA Y METAANÁLISIS
 
Kahn R, Davidson MB. The reality of type 2 diabetes prevention. Diabetes Care 2014;37:943-949 [R,I]
24652724             R/C
LA REALIDAD DE LA PREVENCIÓN DE LA DIABETES TIPO 2
 
Bray GA, Popkin BM. Dietary sugar and body weight: have we reached a crisis in the epidemic of obesity and diabetes?: health be damned! Pour on the sugar. Diabetes Care 2014;37:950-956 [R,I]
24652725             R/C
AZÚCAR EN LA DIETA Y PESO CORPORAL: ¿HEMOS ALCANZADO UNA CRISIS EN LA EPIDEMIA DE OBESIDAD Y DIABETES? ¡QUÉ MÁS DA LA SALUD, ECHA TODO EL AZÚCAR!
 
Kahn R, Sievenpiper JL. Dietary sugar and body weight: have we reached a crisis in the epidemic of obesity and diabetes?: we have, but the pox on sugar is overwrought and overworked. Diabetes Care 2014;37:957-962 [R,I]
24652726             R/C
AZÚCAR EN LA DIETA Y PESO CORPORAL: ¿HEMOS ALCANZADO UNA CRISIS EN LA EPIDEMIA DE OBESIDAD Y DIABETES?: SÍ, PERO SE HA ESCRITO DEMASIADO Y SE HA TRABAJADO DEMASIADO SOBRE LA PLAGA DEL AZÚCAR
 
Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, et al; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. Diabetes Care 2014;37:979-984 [T,II]
24550217             R/C
USO DE LA TABLA DPTRS PARA MEJORAR LA EXACTITUD DE LA CLASIFICACIÓN DEL RIESGO DE DIABETES TIPO 1
 
Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care 2014;37:985-992 [T,II]
24198301             R/C
TRATAMIENTO AMBULATORIO DE LA DIABETES TIPO 2 EN EE UU, 1997-2012
 
Tsai CW, Grams ME, Inker LA, Coresh J, Selvin E. Cystatin C- and creatinine-based estimated glomerular filtration rate, vascular disease, and mortality in persons with diabetes in the U.S. Diabetes Care 2014;37:1002-1008 [T,II]
24271191             R/C
CÁLCULO DE LA TASA DE FILTRACIÓN GLOMERULAR BASADO EN LA CISTATINA C Y EN LA CREATININA, ENFERMEDAD VASCULAR Y MORTALIDAD EN PERSONAS CON DIABETES EN EE UU
 
Sadarangani KP, Hamer M, Mindell JS, Coombs NA, Stamatakis E. Physical activity and risk of all-cause and cardiovascular disease mortality in diabetic adults from Great Britain: pooled analysis of 10 population-based cohorts. Diabetes Care 2014;37:1016-1023 [S,II]
24652727             R/C
ACTIVIDAD FÍSICA Y RIESGO DE MORTALIDAD POR ENFERMEDAD CARDIOVASCULAR Y POR CUALQUIER CAUSA EN ADULTOS DIABÉTICOS DE GRAN BRETAÑA: ANÁLISIS COMBINADO DE 10 COHORTES POBLACIONALES
 
Cox AJ, Hsu FC, Ng MC, Langefeld CD, Freedman BI, Carr JJ, et al. Genetic risk score associations with cardiovascular disease and mortality in the Diabetes Heart study. Diabetes Care 2014;37:1157-1164 [T,II]
24574349             R/C
ASOCIACIONES DE LAS PUNTUACIONES DE RIESGO GENÉTICO CON LA ENFERMEDAD CARDIOVASCULAR Y LA MORTALIDAD EN EL ESTUDIO DIABETES HEART
 
 
Domingo C. Omalizumab for severe asthma: efficacy beyond the atopic patient? Drugs 2014;74:521-533 [R,I]
24691707             R/C
OMALIZUMAB PARA EL ASMA GRAVE: ¿EFICACIA MÁS ALLÁ DEL PACIENTE ATÓPICO?
 
Cazzola M, Segreti A. Omalizumab: stepping outside our comfort zone to broaden the number of those who can benefit. Drugs 2014;74:535-537 [AO,I]
OMALIZUMAB: SALIR DE NUESTRA ZONA DE CONFORT PARA AMPLIAR EL NÚMERO DE LOS QUE SE PUEDEN BENEFICIAR
 
Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2014;74:587-610 [R,II]
24638989             R/C
VILDAGLIPTINA: REVISIÓN DE SU USO EN LA DIABETES MELLITUS TIPO 2
 
Löhle M, Ramberg CJ, Reichmann H, Schapira AH. Early versus delayed initiation of pharmacotherapy in Parkinson's disease. Drugs 2014;74:645-657 [R,I]
24756431             R/C
INICIACIÓN DE FARMACOTERAPIA PRECOZ FRENTE A DIFERIDA EN LA ENFERMEDAD DE PARKINSON
 
Mattishent K, Thavarajah M, Blanco P, Gilbert D, Wilson AM, Loke YK. Meta-review: adverse effects of inhaled corticosteroids relevant to older patients. Drugs 2014 [Epub ahead of print] [M,II]
24659375             R/C
METARREVISIÓN: EFECTOS ADVERSOS DE LOS CORTICOIDES INHALADOS CON RELEVANCIA EN LOS PACIENTES MAYORES
 
 
Fernández S, Del Val M, Fernández T, Fernández ML. Prácticas y percepción del riesgo en hombres con infección por el virus de la inmunodeficiencia humana que tienen sexo con otros hombres. Enferm Infecc Microbiol Clin 2014;32:219-224 [T,I]
23896320             R/C
PRÁCTICAS Y PERCEPCIÓN DEL RIESGO EN HOMBRES CON INFECCIÓN POR EL VIRUS DE LA INMUNODEFICIENCIA HUMANA QUE TIENEN SEXO CON OTROS HOMBRES
 
Julián-Jiménez A, Timón J, Laserna EJ, Sicilia-Bravo I, Palomo-de Los Reyes MJ, Cabezas-Martínez A, et al. Poder diagnóstico y pronóstico de los biomarcadores para mejorar el manejo de la neumonía adquirida en la comunidad en los servicios de urgencias. Enferm Infecc Microbiol Clin 2014;32:225-235 [S,I]
24182623             R/C
PODER DIAGNÓSTICO Y PRONÓSTICO DE LOS BIOMARCADORES PARA MEJORAR EL MANEJO DE LA NEUMONÍA ADQUIRIDA EN LA COMUNIDAD EN LOS SERVICIOS DE URGENCIAS
 
 
Cairns BJ, Baigent C. Air pollution and traffic noise: do they cause atherosclerosis? Eur Heart J 2014;35:826-828 [T,II]
CONTAMINACIÓN DEL AIRE Y RUIDO DEL TRÁFICO ¿CAUSAN ATEROSCLEROSIS?
 
Münzel T, Gori T, Babisch W, Basner M. Cardiovascular effects of environmental noise exposure. Eur Heart J 2014;35:829-836 [R,II]
24616334             R/C
EFECTOS CARDIOVASCULARES DE LA EXPOSICIÓN AL RUIDO AMBIENTAL
 
van der Leeuw J, Ridker PM, van der Graaf Y, Visseren FL. Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects. Eur Heart J 2014;35:837-843 [R,I]
24513790             R/C
PREVENCIÓN CARDIOVASCULAR PERSONALIZADA MEDIANTE LA APLICACIÓN DE LA PREDICCIÓN INDIVIDUALIZADA DE LOS EFECTOS DEL TRATAMIENTO
 
Kälsch H, Hennig F, Moebus S, Möhlenkamp S, Dragano N, Jakobs H, et al; Heinz Nixdorf Recall Study Investigative Group. Are air pollution and traffic noise independently associated with atherosclerosis: the Heinz Nixdorf Recall Study. Eur Heart J 2014;35:853-860 [T,II]
24194529             R/C
¿ESTÁN ASOCIADOS LA CONTAMINACIÓN DEL AIRE Y EL RUIDO DEL TRÁFICO DE FORMA INDEPENDIENTE CON LA ATEROSCLEROSIS? EL ESTUDIO HEINZ NIXDORF RECALL
 
Raza A, Bellander T, Bero-Bedada G, Dahlquist M, Hollenberg J, Jonsson M, et al. Short-term effects of air pollution on out-of-hospital cardiac arrest in Stockholm. Eur Heart J 2014;35:861-868. [T,II]
24302272             R/C
EFECTOS A CORTO PLAZO DE LA CONTAMINACIÓN DEL AIRE SOBRE LAS PARADAS CARDIACAS EXTRAHOSPITALARIAS EN ESTOCOLMO
 
Winkel BG, Risgaard B, Sadjadieh G, Bundgaard H, Haunsø S, Tfelt-Hansen J. Sudden cardiac death in children (1-18 years): symptoms and causes of death in a nationwide setting. Eur Heart J 2014;35:868-875 [T,II]
24344190             R/C
MUERTE SÚBITA CARDIACA EN NIÑOS (1-18 AÑOS): SÍNTOMAS Y CAUSAS DE MUERTE EN UN MARCO DE ÁMBITO NACIONAL
 
Vaucher J, Marques-Vidal P, Preisig M, Waeber G, Vollenweider P. Population and economic impact of the 2013 ACC/AHA guidelines compared with European guidelines to prevent cardiovascular disease. Eur Heart J 2014;35:958-959 [AO,II]
IMPACTO POBLACIONAL Y ECONÓMICO DE LAS GUÍAS 2013 DE LA ACC/AHA COMPARADAS CON LAS GUÍAS EUROPEAS PARA PREVENIR LA ENFERMEDAD CARDIOVASCULAR
 
Ray KK, Kastelein JJ, Matthijs Boekholdt S, Nicholls SJ, Khaw KT, Ballantyne CM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014;35:960-968 [T,II]
24639424             R/C
GUÍA 2013 DE LA ACC/AHA SOBRE EL TRATAMIEENTO DEL COLESTEROL EN SANGRE PARA REDUCIR EL RIESGO DE ENFERMEDAD CARDIOVASCULAR ATEROSCLERÓTICA EN ADULTOS: LO BUENO, LO MALO Y LO INCIERTO: COMPARACIÓN CON LAS GUÍAS ESC/EAS PARA EL MANEJO DE LAS DISLIPEMIAS DE 2011
 
 
Steiner BD. Simulation-based teaching: resisting the allure of shiny new toys. Fam Med 2014;46:249-250 [AO,I]
ENSEÑANZA MEDIANTE SIMULACIÓN: RESISTIR LA FASCINACIÓN DE LOS JUGUETES NUEVOS Y BRILLANTES
 
Shershneva M, Kim JH, Kear C, Heyden R, Heyden N, Lee J, et al. Motivational interviewing workshop in a virtual world: learning as avatars. Fam Med 2014;46:251-258 [QE,I]
24788420             R/C
TALLER DE ENTREVISTA MOTIVACIONAL EN UN MUNDO VIRTUAL: APRENDER COMO AVATARES
 
Roseamelia C, Greenwald JL, Bush T, Pratte M, Wilcox J, Morley CP. A qualitative study of medical students in a rural track: views on eventual rural practice. Fam Med 2014;46:259-266 [C,I]
24788421             R/C
ESTUDIO CUALITATIVO DE ESTUDIANTES DE MEDICINA EN UN GRUPO RURAL: PUNTOS DE VISTA SOBRE LA PRÁCTICA RURAL COMO DESTINO
 
 
Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, et al; CNODES Investigators. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014;63:552-558 [M,II]
23856153             R/C
INIBIDORES DE LA BOMBA DE PROTONES Y RIESGO DE HOSPITALIZACIÓN EN LA NEUMONÍA ADQUIRIDA EN LA COMUNIDAD: ESTUDIOS DE COHORTE REPLICADOS CON METAANÁLISIS
 
Acosta A, Abu Dayyeh BK, Port JD, Camilleri M. Recent advances in clinical practice challenges and opportunities in the management of obesity. Gut 2014;63:687-695 [R,I]
24402654             R/C
AVANCES RECIENTES EN LA PRÁCTICA CLÍNICA, RETOS Y OPORTUNIDADES EN EL MANEJO DE LA OBESIDAD
 
 
Elmore JG, Kramer BS. Breast cancer screening: toward informed decisions. JAMA 2014;311:1298-1299 [AO,I]
24691605
CRIBAJE DEL CÁNCER DE MAMA: HACIA DECISIONES INFORMADAS
 
Pisansky TM, Pugh SL, Greenberg RE, Pervez N, Reed DR, Rosenthal SA, et al. Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial. JAMA 2014;311:1300-1307 [EC,I]
24691606             R/C
TADALAFILO EN LA PREVENCIÓN DE LA DISFUNCIÓN ERÉCTIL TRAS RADIOTERAPIA PARA EL CÁNCER DE PRÓSTATA: GRUPO DE RADIOTERAPIA ONCOLÓGICA
 
Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA 2014;311:1327-1335 [R,II]
24691608             R/C
EVALUACIÓN SISTEMÁTICA DE LOS BENEFICIOS Y RIESGOS PARA ORIENTAR LAS DECISIONES SOBRE EL CRIBADO DE CÁNCER DE MAMA
 
Walter LC, Schonberg MA. Screening mammography in older women: a review. JAMA 2014;311:1336-1347 [R,I]
24691609             R/C
MAMOGRAFÍA DE CRIBAJE EN MUJERES MAYORES: REVISIÓN
 
Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder--and its treatment. JAMA 2014;311:1393-1394 [AO,I]
24577059            
CONFRONTAR EL ESTIGMA DEL TRASTORNO POR USO DE OPIOIDES--Y SU TRATAMIENTO
 
Krumholz HM. The new cholesterol and blood pressure guidelines: perspective on the path forward. JAMA 2014;311:1403-1405 [AO,I]
LAS NUEVAS GUÍAS PARA EL COLESTEROL Y LA TENSIÓN ARTERIAL: PERSPECTIVA DEL CAMINO POR DELANTE
 
Muntner P, Colantonio LD, Cushman M, Goff DC Jr, Howard G, Howard VJ, et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA 2014;311:1406-1415 [S,I]
24682252             R/C
VALIDACIÓN DE LAS ECUACIONES DE RIESGO DE ENFERMEDAD CARDIOVASCULAR ATEROSCLERÓTICA COHORTE COMBINADA
 
Navar-Boggan AM, Pencina MJ, Williams K, Sniderman AD, Peterson ED. Proportion of US adults potentially affected by the 2014 hypertension guideline. JAMA 2014;311:1424-1429 [T,I]
24682242             R/C
PROPORCIÓN DE ADULTOS ESTADOUNIDENSES POTENCIALMENTE AFECTADOS POR LA GUÍA DE HIPERTENSIÓN 2014
 
Das RR, Singh M. Oral zinc for the common cold. JAMA 2014;311:1440-1441 [AO,I]
24715076             R/C
ZINC ORAL PARA EL RESFRIADO COMÚN
 
Aune D, Saugstad OD, Henriksen T, Tonstad S. Maternal body mass index and the risk of fetal death, stillbirth, and infant death: a systematic review and meta-analysis. JAMA 2014;311:1536-1546 [M,II]
24737366             R/C
IMC MATERNO Y RIESGO DE MUERTE FETAL, MORTINATALIDAD Y MUERTE INFANTIL: REVISIÓN SISTEMÁTICA Y METAANÁLISIS
 
Clauw DJ. Fibromyalgia: a clinical review. JAMA 2014;311:1547-1555 [R,I]
24737367             R/C
FIBROMIALGIA: REVISIÓN CLÍNICA
 
Grotta JC. tPA for stroke: important progress in achieving faster treatment. JAMA 2014;311:1615-1617 [AO,I]
tPA EN EL ICTUS: PROGRESO IMPORTANTE PARA ALCANZAR UN TRATAMIENTO MÁS RÁPIDO
 
Ebinger M, Winter B, Wendt M, Weber JE, Waldschmidt C, Rozanski M, et al; STEMO Consortium. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial. JAMA 2014;311:1622-1631 [EC,II]
24756512             R/C
EFECTO DEL USO DE TROMBOLISIS AMBULATORIA SOBRE EL TIEMPO PARA LA TROMBOLISIS EN EL ICTUS ISQUÉMICO AGUDO: ENSAYO CLÍNICO ALEATORIZADO
 
Fonarow GC, Zhao X, Smith EE, Saver JL, Reeves MJ, Bhatt DL, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA 2014;311:1632-1640 [S,I]
24756513             R/C
TIEMPOS DE PUERTA A AGUJA PARA LA ADMINISTRACIÓN DE tPA Y RESULTADOS CLÍNICOS EN EL ICTUS ISQUÉMICO AGUDO ANTES Y DESPUÉS DE UNA INICIATIVA PARA LA MEJORA DE LA CALIDAD
 
Chamberlain JM, Okada P, Holsti M, Mahajan P, Brown KM, Vance C, et al; Pediatric Emergency Care Applied Research Network (PECARN). Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial. JAMA 2014;311:1652-1660 [EC,II]
24756515             R/C
LORAZEPAM FRENTE A DIAZEPAM EN EL ESTATUS EPILÉPTICO PEDIÁTRICO: ENSAYO CLÍNICO ALEATORIZADO
 
Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014;311:1670-1683 [R,I]
24756517             R/C
TRATAMIENTO FARMACOLÓGICO DE LA ENFERMEDAD DE PARKINSON: REVISIÓN
 
Deep brain stimulation for Parkinson's disease with early motor complications. JAMA 2014;311:1686-1687 [AO,I]
ESTIMULACIÓN CEREBRAL PROFUNDA EN LA ENFERMEDAD DE PARKINSON CON COMPLICACIONES MOTRICES PRECOCES
 
 
Yang Q, Zhang Z, Gregg EW, Flanders WD, Merritt R, Hu FB. Added sugar intake and cardiovascular diseases mortality among US adults. JAMA Intern Med 2014;174:516-524 [S,II]
24493081             R/C
CONSUMO DE AZÚCAR AÑADIDO Y MORTALIDAD POR ENFERMEDADES CARDIOVASCULARES ENTRE ADULTOS ESTADOUNIDENSES
 
Yokoyama Y, Nishimura K, Barnard ND, Takegami M, Watanabe M, Sekikawa A, et al. Vegetarian diets and blood pressure: a meta-analysis. JAMA Intern Med 2014;174:577-587 [M,II]
24566947             R/C
DIETAS VEGETARIANAS Y TENSIÓN ARTERIAL: METAANÁLISIS
 
Tinetti ME, Han L, Lee DS, McAvay GJ, Peduzzi P, Gross CP, et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med 2014;174:588-595 [S,II]
24567036             R/C
MEDICACIONES ANTIHIPERTENSIVAS Y DAÑOS GRAVES POR CAÍDAS EN UNA MUESTRA REPRESENTATIVA DE ANCIANOS A NIVEL NACIONAL
 
Carey IM, Shah SM, Dewilde S, Harris T, Victor CR, Cook DG. Increased risk of acute cardiovascular events after partner bereavement: a matched cohort study. JAMA Intern Med 2014;174:598-605 [S,I]
24566983             R/C
AUMENTO DEL RIESGO DE ACONTECIMIENTOS AGUDOS CARDIOVASCULARES TRAS LA PÉRDIDA DE LA PAREJA: ESTUDIO DE COHORTE COMPARADA
 
 
Mostaza JM, Lahoz C. Nuevas pautas en el tratamiento de las dislipidemias. Med Clin (Barc) 2014;142:306-309 [AO,I]
23768860             R/C
NUEVAS PAUTAS EN EL TRATAMIENTO DE LAS DISLIPIDEMIAS
 
Quirce S, Bobolea I, Barranco P. Asma: actualización terapéutica. Med Clin (Barc) 2014;142:317-322 [R,I]
ASMA: ACTUALIZACIÓN TERAPÉUTICA
 
Morell F, Ojanguren I, Cordovilla R, Urrutia I, Agüero R, Guerra J, et al; ASMACAP Study Group. Dos cortas intervenciones reducen la utilización de recursos sanitarios en los pacientes asmáticos. Estudio multicéntrico controlado (ASMACAP II) Med Clin (Barc) 2014;142:348-354 [EC,I]
23932566             R/C
DOS CORTAS INTERVENCIONES REDUCEN LA UTILIZACIÓN DE RECURSOS SANITARIOS EN LOS PACIENTES ASMÁTICOS. ESTUDIO MULTICÉNTRICO CONTROLADO (ASMACAP II)
 
Reina J. Las vacunas cuatrivalentes frente a la gripe estacional. ¿Son la solución definitiva? Med Clin (Barc) 2014;142:355-357 [AO,I]
LAS VACUNAS CUATRIVALENTES FRENTE A LA GRIPE ESTACIONAL. ¿SON LA SOLUCIÓN DEFINITIVA?
 
Fàbregas LA, González-Clemente JM. Prevención cardiovascular primaria con estatinas en la diabetes mellitus tipo 2: ¿es hora de cambiar de estrategia? Med Clin (Barc) 2014;142:358-359 [AO,I]
PREVENCIÓN CARDIOVASCULAR PRIMARIA CON ESTATINAS EN LA DIABETES MELLITUS TIPO 2: ¿ES HORA DE CAMBIAR DE ESTRATEGIA?
 
Robles MJ, Formiga F, Vidán MT. Prevención y tratamiento del delírium en ancianos con fractura de cadera. Med Clin (Barc) 2014;142:365-369 [R,I]
23790577             R/C
PREVENCIÓN Y TRATAMIENTO DEL DELÍRIUM EN ANCIANOS CON FRACTURA DE CADERA
 
Chimenos-Küstner E, Arcos-Guerra C, Marques-Soares MS. Síndrome de boca ardiente: claves diagnósticas y terapéuticas. Med Clin (Barc) 2014;142:370-374 [R,I]
SÍNDROME DE BOCA ARDIENTE: CLAVES DIAGNÓSTICAS Y TERAPÉUTICAS
 
 
Redon J. Mejorando el conocimiento de la hipertensión arterial resistente: ¿qué es relevante? Rev Esp Cardiol 2014;67:251-253 [AO,I]
MEJORANDO EL CONOCIMIENTO DE LA HIPERTENSIÓN ARTERIAL RESISTENTE: ¿QUÉ ES RELEVANTE?
 
Gómez-Doblas JJ, Muñiz J, Martin JJ, Rodríguez-Roca G, Lobos JM, Awamleh P, et al; en representación de los colaboradores del estudio OFRECE. Prevalencia de fibrilación auricular en España. Resultados del estudio OFRECE. Rev Esp Cardiol 2014;67:259-269 [T,II]
24287158             R/C
PREVALENCIA DE FIBRILACIÓN AURICULAR EN ESPAÑA. RESULTADOS DEL ESTUDIO OFRECE
 
Gijón-Conde T, Graciani A, Banegas JR. Demografía y características clínicas de la hipertensión resistente en 6.292 pacientes en atención primaria. Rev Esp Cardiol 2014;67:270-276 [T,I]
24507652             R/C
DEMOGRAFÍA Y CARACTERÍSTICAS CLÍNICAS DE LA HIPERTENSIÓN RESISTENTE EN 6.292 PACIENTES EN ATENCIÓN PRIMARIA
 
Comín-Colet J, Verdú-Rotellar JM, Vela E, Clèries M, Bustins M, Mendoza L, et al; en representación del grupo de trabajo del Programa Integrado de Atención a la Insuficiencia Cardiaca del Área Integral de Salud Barcelona Litoral Mar. Eficacia de un programa integrado hospital-atención primaria para la insuficiencia cardiaca: análisis poblacional sobre 56.742 pacientes. Rev Esp Cardiol 2014;67:283-293 [S,I]
24512985             R/C
EFICACIA DE UN PROGRAMA INTEGRADO HOSPITAL-ATENCIÓN PRIMARIA PARA LA INSUFICIENCIA CARDIACA: ANÁLISIS POBLACIONAL SOBRE 56.742 PACIENTES
 
 
Towards a better life with Alzheimer's disease. Lancet 2014;383:1100 [AO,I]
HACIA UNA MEJOR VIDA CON LA ENFERMEDAD DE ALZHEIMER
 
Pollard AJ, Riordan A, Ramsay M. Group B meningococcal vaccine: recommendations for UK use. Lancet 2014;383):1103-1104 [AO,II]
VACUNA CONTRA EL MENIGOCOCO GRUPO B: RECOMENDACIONES PARA SU USO EN RU
 
Scholl HP, Sahel JA. Gene therapy arrives at the macula. Lancet 2014;383:1105-1107 [AO,I]
LA TERAPIA GÉNICA LLEGA A LA MÁCULA
 
Stoessl AJ. Gene therapy for Parkinson's disease: a step closer? Lancet 2014;383:1107-1109 [AO,I]
TERAPIA GÉNICA PARA LA ENFERMEDAD DE PARKINSON: ¿UN PASO MÁS CERCA?
 
Mental health and wellbeing in children and adolescents. Lancet 2014;383:1183 [AO,I]
SALUD MENTAL Y BIENESTAR EN NIÑOS Y ADOLESCENTES
 
Attia E. Anorexia nervosa in adolescents: challenges remain. Lancet 2014;383:1191-1192 [AO,I]
ANOREXIA NERVIOSA EN ADOLESCENTES: AÚN QUEDAN RETOS
 
A new direction for hepatitis C. Lancet 2014;383:1270 [AO,I]
UNA NUEVA DIRECCIÓN PARA LA HEPATITIS C
 
Greenhawt MJ. STOPping peanut allergy: the saga of food oral immunotherapy. Lancet 2014;383:1272-1274 [AO,I]
DETENER LA ALERGIA A LOS CACAHUETES: LA SAGA DE LA INMUNOTERAPIA ORAL ALIMENTARIA
 
Gale CP, Fox KA. International comparisons of acute myocardial infarction. Lancet 2014;383:1274-1276 [AO,I]
COMPARACIONES INTERNACIONALES DEL INFARTO AGUDO DE MIOCARDIO
 
Macartney K. Prevention of varicella: time for two-dose vaccination. Lancet 2014;383:1276-1277 [AO,II]
PREVENCIÓN DE LA VARICELA: LA HORA DE LA VACUNACIÓN EN DOS DOSIS
 
Tonelli M, Riella M. Chronic kidney disease and the ageing population. Lancet 2014;383:1278-1279 [AO,I]
ENFERMEDAD RENAL CRÓNICA Y POBLACIÓN ENVEJECIDA
 
Health disparities in Europe: hope for the future? Lancet 2014;383:1360 [AO,I]
DISPARIDADES SANITARIAS EN EUROPA: ¿ESPERANZA PARA EL FUTURO?
 
Patton GC, Coffey C, Romaniuk H, Mackinnon A, Carlin JB, Degenhardt L, et al. The prognosis of common mental disorders in adolescents: a 14-year prospective cohort study. Lancet 2014;383:1404-1411 [S,II]
24439298             R/C
PRONÓSTICO DE LOS TRASTORNOS MENTALES MÁS COMUNES EN ADOLESCENTES: ESTUDIO DE COHORTE PROSPECTIVO DE 14 AÑOS
 
Toward better control of colorectal cancer. Lancet 2014;383:1437 [AO,I]
HACIA UN MEJOR CONTROL DEL CÁNCER COLORRECTAL
 
E-cigarettes: closing regulatory gaps. Lancet 2014;383:1438 [AO,I]
CIGARRILLOS ELECTRÓNICOS: CERRAR LOS HUECOS REGULATORIOS
 
 
Gawande AA, Colla CH, Halpern SD, Landon BE. Avoiding low-value care. N Engl J Med 2014;370:e21 [CE,I]
EVITAR LA ATENCIÓN DE POCO VALOR
 
Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370:1287-1297 [T,I]
24645800             R/C
PRUEBA DE ADN EN HECES MULTIDIANA PARA EL CRIBAJE DE CÁNCER COLORRECTAL
 
Corley DA, Jensen CD, Marks AR, Zhao WK, Lee JK, Doubeni CA, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014;370:1298-1306 [T,II]
24693890             R/C
TASA DE DETECCIÓN DE ADENOMAS Y RIESGO DE CÁNCER COLORRECTAL Y DE MUERTE
 
Kamel H, Navi BB, Sriram N, Hovsepian DA, Devereux RB, Elkind MS. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med 2014;370:1307-1315 [S,I]
24524551             R/C
RIESGO DE SUCESO TROMBÓTICO TRAS EL PERIODO DE 6 SEMANAS TRAS EL PARTO
 
Robertson DJ, Dominitz JA. Stool DNA and colorectal-cancer screening. N Engl J Med 2014;370:1350-1351 [AO,I]
ADN EN HECES Y CRIBADO DE CÁNCER COLORRECTAL
 
Huang X, Rosenthal MB. Transforming specialty practice--the patient-centered medical neighborhood. N Engl J Med 2014;370:1376-1379 [AO,II]
TRANSFORMAR LA PRÁCTICA ESPECIALIZADA-EL VECINDARIO MÉDICO CENTRADO EN EL PACIENTE
 
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383-1392 [EC,II]
24716680             R/C
ESPIRONOLACTONA EN LA INSUFICIENCIA CARDIACA CON FRACCIÓN DE EYECCIÓN CONSERVADA
 
Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370:1393-1401 [EC,II]
24678939             R/C
ENSAYO CONTROLADO DE DENERVACIÓN RENAL PARA LA HIPERTENSIÓN RESISTENTE
 
Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, Williams K, Neely B, Sniderman AD, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014;370:1422-1431 [T,II]
24645848             R/C
APLICACIÓN DE LAS NUEVAS GUÍAS PARA EL COLESTEROL A UNA MUESTRA POBLACIONAL
 
McMurray JJ, O'Connor C. Lessons from the TOPCAT trial. N Engl J Med 2014;370:1453-1454 [AO,I]
LECCIONES DEL ENSAYO TOPCAT
 
Messerli FH, Bangalore S. Renal denervation for resistant hypertension? N Engl J Med 2014;370:1454-1457 [AO,I]
¿DENERVACIÓN RENAL EN LA HIPERTENSIÓN RESISTENTE?
 
Devereaux PJ, Mrkobrada M, Sessler DI, Leslie K, Alonso-Coello P, Kurz A, et al; POISE-2 Investigators. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 2014;370:1494-1503 [EC,I]
24679062             R/C
ASPIRINA EN PACIENTES QUE SE SOMETEN A CIRUGÍA NO CARDIACA
 
Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014;370:1514-1523 [T,II]
24738668             R/C
CAMBIOS EN LAS COMPLICACIONES DE LA DIABETES EN LOS ESTADOS UNIDOS
 
Hoofnagle JH, Sherker AH. Therapy for hepatitis C--the costs of success. N Engl J Med 2014;370:1552-1553 [AO,II]
TERAPIA PARA LA HEPATITIS C--LOS COSTES DEL ÉXITO
 
Chung RT, Baumert TF. Curing chronic hepatitis C--the arc of a medical triumph. N Engl J Med 2014;370:1576-1578 [AO,I]
CURA DE LA HEPATITIS C-UN ARCO DEL TRIUNFO DE LA MEDICINA
 
 
Sadatsafavi M, Lynd LD, Marra CA, Fitzgerald JM. Dispensation of long-acting ß agonists with or without inhaled corticosteroids, and risk of asthma-related hospitalisation: a population-based study. Thorax 2014; 69:328-334 [CC,I]
24281327             R/C
DISPENSACIÓN DE AGONISTAS BETA DE LARGA DURACIÓN CON O SIN CORTICOIDES INHALADOS Y RIESGO DE HOSPITALIZACIÓN EN RELACIÓN CON EL ASMA: ESTUDIO POBLACIONAL
 
ACADEMIC MEDICINE
 
Trainees and medical educators hold mismatched impressions of their training programs' balance of service and education. Trainees are more likely to report an overabundance of service. These data may impact the interpretation of Accreditation Council for Graduate Medical Education survey results and should be incorporated into dialogue about future curricular design initiatives.
Difficult conversations about prognosis, end of life, and goals of care arise commonly in medical oncology practice. These conversations are often highly emotional. Medical oncologists need outstanding, patient-centered communication skills to build trust and rapport with their patients and help them make well-informed decisions. Key skills include exploring patients' perspectives, responding to emotion with empathy, and maintaining mindfulness during highly charged conversations. These skills can be taught and learned. Most previously described communication skills training curricula for oncology providers involve multiday retreats, which are costly and can disrupt busy clinical schedules. Many curricula involve a variety of oncology providers, such as physicians and nurses, at various stages of their careers. The authors developed a monthly, one-hour communication skills training seminar series exclusively for physicians in their first year of medical oncology subspecialty training. The curriculum involved a variety of interactive and engaging educational methods, including sociodramatic techniques, role-play, reflective writing, and Balint-type case discussion groups. Medical oncologists in their second and third years of training served as teaching assistants and peer mentors. Learners had the opportunity to practice skills during sessions and with patients between sessions. Learners acquired important skills and found the curriculum to be clinically relevant, judging by anonymous surveys and anonymous responses on reflective writing exercises. Results from the current curriculum are preliminary but lay the foundation for enhanced and expanded communication skills training programs in the future.
The medical literature almost uniformly addresses the positive aspects of role modeling. Still, some authors have questioned its educational value, a disagreement that is probably due to differing definitions of role modeling. If defined as demonstration of skills, provision of feedback, and emulation of specific professional behaviors, then role modeling is an important component of clinical training. However, if it is defined as a learner's unselective imitation of role models and uncritical adoption of the messages of the learning environment, then the benefits of role modeling should be weighed against its unintended harm.In this Perspective, the author argues that imitation of role models may initially help students adapt to the clinical environment. However, if sustained, imitation may perpetuate undesirable practices, such as doctor-centered patient interviewing, and unintended institutional norms, such as discrimination between private and public patients. The author suggests that the value of role modeling can be advanced not only by targeting role models and improving faculty performance but also by enhancing students' reflective assessment of their preceptors' behaviors, especially so that they can better discern those that are worth imitating. This student-centered approach may be accomplished by first, warning students against uncritically imitating preceptors who are perceived as role models; second, showing students that their preceptors share their doubts and uncertainties; third, gaining an insight into possible undesirable messages of the learning environment; and finally, developing policies for faculty recruitment and promotion that consider whether a clinical preceptor is a role model.
Although the study results were obtained via self-report-a limitation-they suggest that the effective simulation of medical consultations with SPs may improve medical students' empathy levels. One unexpected result was that this activity, during the debriefing, became a forum for debating topics such as the doctor-patient relationship, the hidden curriculum, negative role models, and emotionally significant experiences of students in medical school. This kind of activity in itself may influence young doctors to become more empathetic and compassionate with their patients and foster a more meaningful way of practicing medicine.
 
ANNALS OF INTERNAL MEDICINE
 
High-energy ESWT is effective for improving pain and shoulder function in chronic calcific shoulder tendinitis and can result in complete resolution of calcifications. This therapy may be underutilized for a condition that can be difficult to manage.
Primary nonadherence is common and may be reduced by lower drug costs and copayments, as well as increased follow-up care with prescribing physicians for patients with chronic conditions.
Over the past 2 decades, the prevalence of total diabetes has increased substantially. However, the proportion of undiagnosed diabetes cases decreased, suggesting improvements in screening and diagnosis. Among the growing number of persons with diagnosed diabetes, glycemic control improved but remains a challenge, particularly among non-Hispanic blacks and Mexican Americans.
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of multivitamins for the prevention of cardiovascular disease or cancer. (I statement)The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of single- or paired-nutrient supplements (except ß-carotene and vitamin E) for the prevention of cardiovascular disease or cancer. (I statement)The USPSTF recommends against ß-carotene or vitamin E supplements for the prevention of cardiovascular disease or cancer. (D recommendation).
A negative semiquantitative POC test result does not rule out albuminuria, whereas quantitative POC testing meets required performance standards and can be used to rule out albuminuria.
Clinicians could consider using lower-intensity statin combined with bile acid sequestrant or ezetimibe among high-risk patients intolerant of or unresponsive to statins; however, this strategy should be used with caution given the lack of evidence on long-term clinical benefits and harms.
 
ARCHIVOS DE BRONCONEUMOLOGIA
 
The classification of patients with COPD using the assessment proposed by GOLD2011 varies according to the method used (CAT or mMRC); more than 25% of patients were reclassified into different categories, implying differences in the recommended therapeutic strategy. Longitudinal studies are needed to appraise which method better classifies patients, according to its prognostic ability.
 
ATENCION PRIMARIA
 
Los índices BODE y ADO presentaron una importante asociación con la CVRS. Las exacerbaciones y la disnea fueron los factores individuales que mejor se relacionaron con la CVRS.
Con la introducción de la historia clínica digital surge la necesidad de reforzar la seguridad de los datos personales de salud para garantizar su privacidad. A pesar de la gran cantidad de medidas de seguridad técnicas y de recomendaciones existentes para el ámbito sanitario, hay un aumento en las violaciones de la privacidad de los datos personales de los pacientes en centros sanitarios, en muchos casos como consecuencia de errores o descuidos de los profesionales sanitarios. En este trabajo se presenta una guía de buenas prácticas de seguridad informática en la manipulación de los datos personales de salud por parte del personal sanitario, elaborada a partir de recomendaciones, normativa y estándares nacionales e internacionales. El material presentado en este trabajo puede emplearse tanto en la formación como en auditorías de seguridad informática a trabajadores de los centros de atención primaria.
 
BRITISH MEDICAL JOURNAL
 
In prophylactic studies oseltamivir reduces the proportion of symptomatic influenza. In treatment studies it also modestly reduces the time to first alleviation of symptoms, but it causes nausea and vomiting and increases the risk of headaches and renal and psychiatric syndromes. The evidence of clinically significant effects on complications and viral transmission is limited because of rarity of such events and problems with study design. The trade-off between benefits and harms should be borne in mind when making decisions to use oseltamivir for treatment, prophylaxis, or stockpiling.
L reuteri DSM 17938 did not benefit a community sample of breastfed infants and formula fed infants with colic. These findings differ from previous smaller trials of selected populations and do not support a general recommendation for the use of probiotics to treat colic in infants.
Despite a few hundred systematic reviews and meta-analyses, highly convincing evidence of a clear role of vitamin D does not exist for any outcome, but associations with a selection of outcomes are probable.
Evidence from observational studies indicates inverse associations of circulating 25-hydroxyvitamin D with risks of death due to cardiovascular disease, cancer, and other causes. Supplementation with vitamin D3 significantly reduces overall mortality among older adults; however, before any widespread supplementation, further investigations will be required to establish the optimal dose and duration and whether vitamin D3 and D2 have different effects on mortality risk.
Based on a full assessment of all trials conducted, zanamivir reduces the time to symptomatic improvement in adults (but not in children) with influenza-like illness by just over half a day, although this effect might be attenuated by symptom relief medication. Zanamivir also reduces the proportion of patients with laboratory confirmed symptomatic influenza. We found no evidence that zanamivir reduces the risk of complications of influenza, particularly pneumonia, or the risk of hospital admission or death. Its harmful effects were minor (except for bronchospasm), perhaps because of low bioavailability.
This systematic review, reporting meta-analysed data from studies of pregnant women with chronic hypertension, shows that adverse outcomes of pregnancy are common and emphasises a need for heightened antenatal surveillance. A consistent strategy to study women with chronic hypertension is needed, as previous study designs have been diverse. These findings should inform counselling and contribute to optimisation of maternal health, drug treatment, and pre-pregnancy management in women affected by chronic hypertension.
The STONE score reliably predicts the presence of uncomplicated ureteral stone and lower likelihood of acutely important alternative findings. Incorporation in future investigations may help to limit exposure to radiation and over-utilization of imaging.
Compelling and consistent evidence from randomised controlled trials and observational studies suggests that screening sigmoidoscopy and screening colonoscopy prevent most deaths from distal colorectal cancer. Observational studies suggest that colonoscopy compared with flexible sigmoidoscopy decreases mortality from cancer of the proximal colon. This added value should be examined in further research and weighed against the higher costs, discomfort, complication rates, capacities needed, and possible differences in compliance.
These novel global data on dietary fats and oils identify dramatic diversity across nations and inform policies and priorities for improving global health.
Compared with use of sulfonylureas, the use of incretin based drugs is not associated with an increased risk of acute pancreatitis. While this study is reassuring, it does not preclude a modest increased risk, and thus additional studies are needed to confirm these findings.
The available evidence suggests that the incidence of pancreatitis among patients using incretins is low and that the drugs do not increase the risk of pancreatitis. Current evidence, however, is not definitive, and more carefully designed and conducted observational studies are warranted to definitively establish the extent, if any, of increased risk.
The ratio of benefits to harms of PSA screening varies noticeably with blood PSA levels at age 60. For men with a PSA level <1 ng/mL at age 60, no further screening is recommended. Continuing to screen men with PSA levels >2 ng/mL at age 60 is beneficial, with the number needed to screen and treat being extremely favourable. Screening men with a PSA level of 1-2 ng/mL is an individual decision to be based on a discussion between patient and doctor.
Atrial fibrillation increases the risk of stroke, which is a leading cause of death and disability worldwide. The use of oral anticoagulation in patients with atrial fibrillation at moderate or high risk of stroke, estimated by established criteria, improves outcomes. However, to ensure that the benefits exceed the risks of bleeding, appropriate patient selection is essential. Vitamin K antagonism has been the mainstay of treatment; however, newer drugs with novel mechanisms are also available. These novel oral anticoagulants (direct thrombin inhibitors and factor Xa inhibitors) obviate many of warfarin's shortcomings, and they have demonstrated safety and efficacy in large randomized trials of patients with non-valvular atrial fibrillation. However, the management of patients taking warfarin or novel agents remains a clinical challenge. There are several important considerations when selecting anticoagulant therapy for patients with atrial fibrillation. This review will discuss the rationale for anticoagulation in patients with atrial fibrillation; risk stratification for treatment; available agents; the appropriate implementation of these agents; and additional, specific clinical considerations for treatment.
 
BRITISH JOURNAL OF PSYCHIATRY
 
Prevention of mental disorders can be effective, but is rarely implemented in routine settings. Here we propose a matrix to show how different aspects of stigma, discrimination and lack of knowledge can hinder different types of prevention, including early intervention. Programmes to reduce stigma's impact and so to facilitate prevention are needed.
Frequent religious service attendance is a long-term protective factor against suicide.
Much of the evidence that religion provides a protective factor against completed suicide comes from cross-sectional studies. This issue of the Journal includes a report of a new prospective study. An understanding of the relationship between spirituality, religion and suicide is important in assessing and caring for those at risk.
Suicide prevention activity, including a better psychiatric evaluation of patients within general hospital settings deserves more attention. Improved information flow between secondary and primary care could be facilitated by exploiting electronic records of previous psychiatric diagnoses.
 
CANADIAN MEDICAL ASSOCIATION JOURNAL
 
Sleep apnea appeared to confer a higher risk for future pneumonia, possibly in a severity-dependent manner.
In Canada, many patients with COPD suffer a serious adverse event or death after being discharged home from the emergency department. We identified high-risk characteristics and developed a preliminary risk scale that, once validated, could be used to stratify the likelihood of poor outcomes and to enable rational and safe admission decisions.
 
CIRCULATION
 
In most world regions, particularly in high-income regions, age-standardized IHD mortality rates have declined significantly since 1980. High age-standardized IHD mortality in Eastern Europe, Central Asia, and South Asia point to the need to prevent and control established risk factors in those regions and to research the unique behavioral and environmental determinants of higher IHD mortality.
Globally, age-standardized acute myocardial infarction incidence and angina prevalence have decreased, and ischemic heart failure prevalence has increased since 1990. Despite decreased age-standardized fatal and nonfatal IHD in most regions since 1990, population growth and aging led to a higher global burden of IHD in 2010.
There is a large global variation in age, risk factors, concomitant diseases, and treatment of AF among regions. Improving outcomes globally requires an understanding of this variation and the conduct of research focused on AF associated with different underlying conditions and treatment of AF and predisposing conditions in different socioeconomic settings.
In atrial fibrillation patients with stable coronary artery disease, the addition of antiplatelet therapy to VKA therapy is not associated with a reduction in risk of recurrent coronary events or thromboembolism, whereas risk of bleeding is increased significantly. The common practice of adding antiplatelet therapy to oral VKA anticoagulation in patients with atrial fibrillation and stable coronary artery disease warrants reassessment.
This study demonstrates widespread suboptimal anticoagulation control, suggesting an urgent need to improve oral anticoagulation care for most patient segments in the United States.
 
DIABETES CARE
 
More persons with diabetes had reduced kidney function by eGFRcys than by eGFRcr, and lower eGFRcys was strongly associated with diabetes complications. Whether eGFRcys is superior to eGFRcr in approximating true kidney function in a diabetic population requires additional study.
These data suggest that a diabetes-associated GRS is associated with development of GDM and may characterize women at risk for development of diabetes due to ß-cell dysfunction.
These findings support the utility of two simple GRSs in examining genetic associations for adverse outcomes in EAs with type 2 diabetes.
Ocular anti-vascular endothelial growth factor (VEGF) therapy represents one of the most significant advances in modern medicine. The introduction and widespread use of ocular anti-VEGF therapy for age-related macular degeneration heralded a new era in the treatment of vascular and exudative diseases of the retina. Its expanding indications now include diabetic macular edema and proliferative diabetic retinopathy, two vision-threatening forms of diabetic retinopathy. It is widely anticipated that ocular anti-VEGF therapy could spark a dramatic shift in the treatment paradigm for diabetic retinopathy. However, despite its clear efficacy shown in clinical trials, the dynamic landscape of evolving medical, ethical, and economic issues related to this new treatment suggests significant challenges ahead. In this article, we provide a discussion of this topic as part of this two-part Bench to Clinic narrative. Here, our Clinic contribution provides an overview of the current evidence from clinical trials on anti-VEGF therapy for diabetic retinopathy, and highlights the hopes and fears of this new treatment from clinical and public health standpoints. In the Bench narrative that precedes this contribution, Simó et al. provide an overview of the role of VEGF in the pathogenesis of diabetic retinopathy.
Diabetic retinopathy is the leading cause of visual impairment and preventable blindness, and represents a significant socioeconomic cost for health care systems worldwide. Therefore, new approaches beyond current standards of diabetes care are needed. Based on the crucial pathogenic role of vascular endothelial growth factor (VEGF) in the development of diabetic macular edema (DME), intravitreal anti-VEGF agents have emerged as new treatments. To provide an understanding of the rationale for use and clinical efficacy of anti-VEGF treatment, we examine this topic in a two-part Bench to Clinic narrative. In the Bench narrative, we provide an overview of the role of VEGF in the pathogenesis of diabetic retinopathy, the molecular characteristics of anti-VEGF agents currently used, and future perspectives and challenges in this area. In the Clinic narrative that follows our contribution, Cheung et al. provide an overview of the current evidence from clinical trials on anti-VEGF therapy for diabetic retinopathy.
Moderate physical activity levels were associated with better prognosis in diabetic adults.
PHEN/TPM ER plus lifestyle modification produced significant weight loss and markedly reduced progression to type 2 diabetes in overweight/obese patients with prediabetes and/or MetS, accompanied by improvements in multiple cardiometabolic disease risk factors.
Efforts to reduce the burden of type 2 diabetes include attempts to prevent or delay the onset of the disease. Landmark clinical trials have shown that lifestyle modification programs focused on weight loss can delay the onset of type 2 diabetes in subjects at high risk of developing the disease. Building on this knowledge, many community-based studies have attempted to replicate the trial results and, simultaneously, payers have begun to cover diabetes prevention services. This article focuses on the evidence supporting the premise that community prevention efforts will be successful. Unfortunately, no study has shown that diabetes can be delayed or prevented in a community setting, and efforts to replicate the weight loss achieved in the trials have been mostly disappointing. Furthermore, both the clinical trials and the community-based prevention studies have not shown a beneficial effect on any diabetes-related clinical outcome. While the goal of diabetes prevention is extremely important, the absence of any persuasive evidence for the effectiveness of community programs calls into question whether the use of public funds or national prevention initiatives should be supported at this time.
DPTRS thresholds can improve T1D risk classification accuracy by identifying high-risk normoglycemic and low-risk dysglycemic individuals. The 7.00 DPTRS threshold characterizes risk more consistently between populations and has greater reliability than dysglycemia.
Declining sulfonylurea and glitazone use has been offset by increases in DPP-4 inhibitor use and, to a lesser degree, use of GLP-1 agonists. Treatment of diabetes has grown in complexity while older treatments continue to be replaced or supplemented by newer therapies.
Evidence suggests that pragmatic diabetes prevention programs are effective. Effectiveness varies substantially between programs but can be improved by maximizing guideline adherence. However, more research is needed to establish optimal strategies for maximizing both cost-effectiveness and longer-term maintenance of weight loss and diabetes prevention effects.
In the preceding point narrative, Drs. Bray and Popkin provide their opinion and review data that suggest to them that we need to reconsider the consumption of dietary sugar based on the growing concern of obesity and type 2 diabetes. In the counterpoint narrative below, we argue that there is no clear or convincing evidence that any dietary or added sugar has a unique or detrimental impact relative to any other source of calories on the development of obesity or diabetes. Sugar is purely a highly palatable source of energy; because it has no other property that appears to contribute to our nutritional well-being, it is not an essential food for most of us. For those who wish to reduce energy consumption, ingesting less sugar is a good place to start. However, doing so does not automatically portend any clinical benefit.
Sugar-sweetened drinks have been associated with several health problems. In the point narrative as presented below, we provide our opinion and review of the data to date that we need to reconsider consumption of dietary sugar based on the growing concern of obesity and type 2 diabetes. In the counterpoint narrative following our contribution, Drs. Kahn and Sievenpiper provide a defense and suggest that dietary sugar is not the culprit. Data from the National Health and Nutrition Examination Survey and U.S. Department of Agriculture dietary surveys along with commercial Homescan data on household purchases were used to understand changes in sugar and fructose consumption. Meta-analyses and randomized clinical trials were used to evaluate outcomes of beverage and fructose intake. About 75% of all foods and beverages contain added sugar in a large array of forms. Consumption of soft drinks has increased fivefold since 1950. Meta-analyses suggest that consumption of sugar-sweetened beverages (SSBs) is related to the risk of diabetes, the metabolic syndrome, and cardiovascular disease. Drinking two 16-ounce SSBs per day for 6 months induced features of the metabolic syndrome and fatty liver. Randomized controlled trials in children and adults lasting 6 months to 2 years have shown that lowering the intake of soft drinks reduced weight gain. Recent studies suggest a gene-SSB potential relationship. Consumption of calorie-sweetened beverages has continued to increase and plays a role in the epidemic of obesity, the metabolic syndrome, and fatty liver disease. Reducing intake of soft drinks is associated with less weight gain.
 
DRUGS
 
Several years ago, omalizumab became commercially available for the treatment of severe asthma. It remains the only monoclonal antibody to be marketed for this purpose. Since then, many studies have been published endorsing its efficacy and effectiveness. Concomitantly, evidence of an overlap between atopic and non-atopic severe asthma has emerged. However, there also appears to be some disagreement regarding the value of omalizumab in the management of non-atopic disease, as some studies have failed to show any benefit in these patients. The recent literature has also sought to identify appropriate prognostic biomarkers for the use of omalizumab, other than immunoglobulin (IgE) levels. This article briefly summarizes the evolution of asthma treatment, the pathophysiology of the condition, and the method of action of omalizumab. The author describes the controlled and uncontrolled studies (also named "real-life studies") published in adult and pediatric populations in different countries and expresses his view on the current place of the drug in the management of severe allergic asthma. He offers a personal perspective on the recent evidence for the use of omalizumab in non-atopic patients, highlighting the implications for current clinical practice and the gaps in our knowledge. The author justifies his belief that omalizumab is not only an IgE-blocking drug and should be considered as a disease-modifying therapy because of its multiple effects on different biologic pathways. Finally, some areas for future research are indicated.
The dipeptidyl peptidase-4 inhibitor vildagliptin (Galvus(®)) is approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. A fixed-dose combination of vildagliptin/metformin (Eucreas(®)) is also available. This article reviews the clinical efficacy and tolerability of vildagliptin in the treatment of type 2 diabetes, as well as summarizing its pharmacological properties. Results of randomized controlled trials demonstrated that oral vildagliptin improved glycaemic control when administered as monotherapy, as dual therapy in combination with metformin, a sulfonylurea or a thiazolidinedione, as triple therapy in combination with metformin plus a sulfonylurea, and in combination with insulin with or without metformin. Improvements in glycaemic control were also seen with vildagliptin in elderly patients with type 2 diabetes and in patients with type 2 diabetes and moderate or severe renal impairment. Vildagliptin was generally well tolerated in patients with type 2 diabetes, was weight neutral and was associated with a low risk of hypoglycaemia, reflecting its glucose-dependent mechanism of action. Thus, oral vildagliptin is a useful option as monotherapy or as add-on therapy for patients with type 2 diabetes.
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease and pathologically is characterised by a progressive loss of dopaminergic cells of the nigrostriatal pathway. Clinically, PD is mainly defined by the presence of the motor symptoms of bradykinesia, rigidity, rest tremor and postural instability, but non-motor symptoms such as depression, dementia and autonomic disturbances are recognised as integral parts of the disease. Although pharmacotherapy for PD was introduced almost 50 years ago, and has improved significantly over the intervening period, the timing of initiation of treatment in newly diagnosed PD remains controversial. While some physicians favour an early start of pharmacotherapy at or soon after diagnosis, others prefer to delay pharmacological treatment until a certain degree of disability has developed. This article aims to discuss the advantages and disadvantages of both strategies by exploring their effects on symptoms, disease progression and quality of life. Although the data on putative disease-modifying effects of early pharmacological intervention in PD are still inconclusive, we believe that the most important indication for an early initiation of anti-parkinsonian treatment should be to maintain the quality of life of PD patients and to secure their socioeconomic status as long as possible.
In view of the dose-response relationship seen between ICS use and important adverse effects such as fractures and pneumonia, clinicians needs to carefully balance the benefits of ICS versus the harms in older patients receiving long-term high-dose ICS.
 
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
 
La gestión del riesgo de adquirir VIH se hace desde un grado de preocupación bajo, motivado por el optimismo fruto de los avances en la lucha contra la enfermedad y la dulcificación actual del discurso. La banalización del riesgo, al desvirtuar la idea de conducta arriesgada, es un determinante de actitudes que imposibilitarían adoptar un comportamiento preventivo eficaz y tomar decisiones prudentes y anticipadas.
En los pacientes con NAC la MR-proADM y el lactato presentan una capacidad pronóstica de mortalidad intrahospitalaria a los 30 días similar o superior al PSI, CURB-65, SET y criterios de NAC grave (p > 0,05), mientras que para la predicción de mortalidad a 180 días la MR-proADM es superior a las EPG y al resto de biomarcadores (p < 0,05), y aumenta su ABC al combinarla con el PSI, CURB-65 y SET. Por otro lado, la PCT consigue un gran rendimiento diagnóstico para descartar bacteriemia y orientar la etiología por S. pneumoniae.
 
EUROPEAN HEART JOURNAL
 
Large-scale randomized clinical trials have established the efficacy of cholesterol-lowering, blood pressure-lowering, and anti-platelet therapy to prevent cardiovascular diseases. A challenge for clinicians is to apply group-level evidence from these trials to individual patients. Trials typically report a single treatment effect estimate which is the average effect of all participants, comprising patients who respond poorly, intermediately, and well. Clinicians would preferably make patient-tailored treatment decisions. Therefore, one would require an estimate of an individual patient's response to therapy. Although not yet widely recognized, trials contain this type of information. In this paper, we show how available information from landmark trials can be translated to an individual 'treatment score' through the use of multivariable therapeutic prediction models. These models provide an individual estimate of the absolute risk reduction in cardiovascular events given the specific combination of multiple clinical characteristics of a patient under care. Based on this individualized treatment estimate and metrics such as the individual number-needed-to-treat, clinicians together with their patients can decide whether drug treatment or what treatment intensity is worthwhile. Selective treatment of those who can anticipate the greatest benefit and the least harm on an individualized basis could reduce the number of unnecessary treatments and healthcare costs beyond that currently achievable by subgroup analyses based on single patient characteristics.
Short-term exposure to moderate levels of O3 is associated with an increased risk of OHCA.
From a nationwide study of all deaths in a 7-year period more than half of all victims of SCDc experienced antecedent and/or prodromal symptoms prior to death. The incidence rate of sudden death and SCDc was 1.5 and 1.1 per 100 000 person-years, respectively. Cardiac symptoms in young persons should warrant clinical work-up and an autopsy should be performed in all cases of sudden unexpected death in which the deceased was not known with congenital heart disease prior to death. This is pivotal, in the subsequent familial cascade screening, to diagnose and treat potential inherited cardiac diseases in family members.
Atherosclerotic cardiovascular disease is the most important public health problem of our time in both Europe and the rest of the world, accounting for the greatest expenditure in most healthcare budgets. Achieving consistency of clinical care, incorporating new evidence and their synthesis into practical recommendations for clinicians is the task of various guideline committees throughout the world. Any change in a set of guidelines therefore can have far reaching consequences, particularly if they appear to be at variance with the existing guidelines. The present article discusses the recent American College of Cardiology (ACC)/American Heart Association (AHA) guidelines 2013 on the control of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults. When compared with the ESC/EAS guidelines on lipid modification in 2011, the ACC/AHA guidelines of 2013 differ markedly. Specifically, (i) the scope is limited to randomized trials only, which excludes a significant body of data and promotes essentially a statin centric approach only; (ii) the abolition of low-density lipoprotein cholesterol (LDL-C) targets in favour of specific statin regimens that produce a 30-50% reduction in LDL-C we believe will confuse many physicians and miss the opportunity for medication adherence and patient engagement in self-management; (iii) the absence of target LDL-C levels in very high-risk patients with high absolute risk or residual risk factors will discourage clinicians to consider the addition of lipid modification treatments and individualize patient care; (iv) a reduction in the threshold for treatment in primary prevention will result in a greater number of patients being prescribed statin therapy, which is potentially good in young patients with high life time risk, but will result in a very large number of older patients offered therapy; and (v) the mixed pool risk calculator used to asses CVD risk in the guidelines for primary prevention has not been fully evaluated. This article discusses the potential implications of adopting the ACC/AHA guidelines on patient care in Europe and beyond and concludes with the opinion that the ESC/EAS guidelines from 2011 seem to be the most wide ranging, pragmatic and appropriate choice for European countries.
Long-term exposure to fine PM and night-time traffic noise are both independently associated with subclinical atherosclerosis and may both contribute to the association of traffic proximity with atherosclerosis.
The role of noise as an environmental pollutant and its impact on health are being increasingly recognized. Beyond its effects on the auditory system, noise causes annoyance and disturbs sleep, and it impairs cognitive performance. Furthermore, evidence from epidemiologic studies demonstrates that environmental noise is associated with an increased incidence of arterial hypertension, myocardial infarction, and stroke. Both observational and experimental studies indicate that in particular night-time noise can cause disruptions of sleep structure, vegetative arousals (e.g. increases of blood pressure and heart rate) and increases in stress hormone levels and oxidative stress, which in turn may result in endothelial dysfunction and arterial hypertension. This review focuses on the cardiovascular consequences of environmental noise exposure and stresses the importance of noise mitigation strategies for public health.
 
FAMILY MEDICINE
 
Students with rural and primary care practice interests are often not perfectly committed to rural practice. However, RTs may provide a haven for such students within medical school.
The evaluated workshop had positive impact on participants' competencies and practice as related to MI applied to smoking cessation counseling. Our findings support further exploration of three-dimensional virtual worlds as learning environments for continuing medical education.
 
GUT
 
Despite advances in understanding the roles of adiposity, food intake, GI and adipocyte-related hormones, inflammatory mediators, the gut-brain axis and the hypothalamic nervous system in the pathophysiology of obesity, the effects of different therapeutic interventions on those pathophysiological mechanisms are controversial. There are still no low-cost, safe, effective treatments for obesity and its complications. Currently, bariatric surgical approaches targeting the GI tract are more effective than non-surgical approaches in inducing weight reduction and resolving obesity-related comorbidities. However, current guidelines emphasise non-surgical approaches through lifestyle modification and medications to achieve slow weight loss, which is not usually sustained and may be associated with medication-related side effects. This review analyses current central, peripheral or hormonal targets to treat obesity and addresses challenges and opportunities to develop novel approaches for obesity.
Our study does not support the proposition of a pharmacological effect of gastric acid suppressors on the risk of HCAP.
 
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
 
CLINICAL QUESTION:
Is oral zinc associated with a shorter duration, decreased severity, and reduced incidence of the common cold compared with placebo?
BOTTOM LINE:
When initiated within 24 hours of symptom onset, oral zinc is associated with a shorter duration of the common cold in healthy people. However, there is no association between oral zinc and symptom severity, and the prevalence of adverse effects with zinc lozenges is high. Given the high heterogeneity of data, these results should be interpreted with caution. Used prophylactically, oral zinc is associated with a reduced cold incidence in children. Prophylactic use has not been studied in adults.
Strong evidence supports using levodopa and dopamine agonists for motor symptoms at all stages of Parkinson disease. Dopamine agonists and drugs that block dopamine metabolism are effective for motor fluctuations and clozapine is effective for hallucinations. Cholinesterase inhibitors may improve symptoms of dementia and antidepressants and pramipexole may improve depression. Evidence supporting other therapies for motor and nonmotor features is less well established.
Compared with the JNC 7 guideline, the 2014 BP guideline from the panel members appointed to the JNC 8 was associated with a reduction in the proportion of US adults recommended for hypertension treatment and a substantial increase in the proportion of adults considered to have achieved goal BP, primarily in older adults.
For women with less than a 10-year life expectancy, recommendations to stop screening mammography should emphasize increased potential harms from screening and highlight health promotion measures likely to be beneficial over the short term. For women with a life expectancy of more than 10 years, deciding whether potential benefits of screening outweigh harms becomes a value judgment for patients, requiring a realistic understanding of screening outcomes.
Among men undergoing radiotherapy for prostate cancer, daily use of tadalafil compared with placebo did not result in improved erectile function. These findings do not support daily use of tadalafil to prevent erectile dysfunction in these patients.
In this cohort of US adults for whom statin initiation is considered based on the ACC/AHA Pooled Cohort risk equations, observed and predicted 5-year atherosclerotic CVD risks were similar, indicating that these risk equations were well calibrated in the population for which they were designed to be used, and demonstrated moderate to good discrimination.
To maximize the benefit of mammography screening, decisions should be individualized based on patients' risk profiles and preferences. Risk models and decision aids are useful tools, but more research is needed to optimize these and to further quantify overdiagnosis. Research should also explore other breast cancer screening strategies.
Implementation of a national quality improvement initiative was associated with improved timeliness of tPA administration following AIS on a national scale, and this improvement was associated with lower in-hospital mortality and intracranial hemorrhage, along with an increase in the percentage of patients discharged home.
Compared with usual care, the use of ambulance-based thrombolysis resulted in decreased time to treatment without an increase in adverse events. Further studies are needed to assess the effects on clinical outcomes.
Fibromyalgia and other "centralized" pain states are much better understood now than ever before. Fibromyalgia may be considered as a discrete diagnosis or as a constellation of symptoms characterized by central nervous system pain amplification with concomitant fatigue, memory problems, and sleep and mood disturbances. Effective treatment for fibromyalgia is now possible.
Among pediatric patients with convulsive status epilepticus, treatment with lorazepam did not result in improved efficacy or safety compared with diazepam. These findings do not support the preferential use of lorazepam for this condition.
Even modest increases in maternal BMI were associated with increased risk of fetal death, stillbirth, and neonatal, perinatal, and infant death. Weight management guidelines for women who plan pregnancies should take these findings into consideration to reduce the burden of fetal death, stillbirth, and infant death.
 
JAMA INTERNAL MEDICINE
 
This study provides further evidence that the death of a partner is associated with a range of major cardiovascular events in the immediate weeks and months after bereavement. Understanding psychosocial factors associated with acute cardiovascular events may provide opportunities for prevention and improved clinical care.
Consumption of vegetarian diets is associated with lower BP. Such diets could be a useful nonpharmacologic means for reducing BP.
Most US adults consume more added sugar than is recommended for a healthy diet. We observed a significant relationship between added sugar consumption and increased risk for CVD mortality.
Antihypertensive medications were associated with an increased risk of serious fall injuries, particularly among those with previous fall injuries. The potential harms vs benefits of antihypertensive medications should be weighed in deciding to continue treatment with antihypertensive medications in older adults with multiple chronic conditions.
 
MEDICINA CLINICA
 
La reducción del riesgo de complicaciones cardiovasculares a través de la modificación de los lípidos sigue actualmente centrada en el descenso del colesterol unido a lipoproteínas de baja densidad, siendo las estatinas los fármacos de elección. Nuevos tratamientos, en fase de investigación, como los anticuerpos que neutralizan la PCSK9, tendrán un lugar reservado para el tratamiento de pacientes con intolerancia a las estatinas o con dislipidemias graves. Los fármacos dirigidos a modificar la concentración de colesterol unido a lipoproteínas de alta densidad y triglicéridos no se han acompañado de las reducciones esperadas en la tasa de complicaciones cardiovasculares.
La fractura del tercio proximal del fémur o fractura de cadera en el anciano suele acontecer tras una caída y comporta una importante morbimortalidad asociada. Una de las complicaciones más frecuentes durante la hospitalización por fractura de cadera es la aparición de delírium o síndrome confusional agudo, que en el paciente anciano tiene un impacto negativo en la estancia hospitalaria y en el pronóstico, empeorando la capacidad funcional, el estado cognitivo y la mortalidad. También, el desarrollo de delírium durante la hospitalización aumenta el gasto sanitario. Las estrategias para prevenir y tratar el delírium durante el ingreso por fractura de cadera han sido menos estudiadas. En este contexto, el presente trabajo tiene como objetivo llevar a cabo una revisión sobre las publicaciones respecto a las estrategias que existen en la prevención y tratamiento del delírium en ancianos con fractura de fémur.
Two short educational interventions improved asthma education and decreased the use of health resources and work absenteeism.
 
REVISTA ESPAÑOLA DE CARDIOLOGIA
 
La prevalencia de fibrilación auricular en la población general española mayor de 40 años es elevada, del 4,4%. La prevalencia es similar en varones y mujeres y se incrementa escalonadamente a partir de los 60 años. Se estima en más de 1 millón de pacientes con fibrilación auricular en la población española, de los que más de 90.000 están sin diagnosticar.
De cada 4 pacientes con hipertensión resistente, 1 es > 80 años. La hipertensión resistente está asociada a la enfermedad cardiovascular, al varón < 50 años y la mujer > 80. La prevalencia de enfermedad cardiovascular en el anciano con hipertensión resistente es elevada.
La implantación de programas multidisciplinarios para la gestión de la insuficiencia cardiaca que integran hospital y comunidad es factible y se asocia a una reducción significativa de la morbimortalidad de los pacientes.
 
THE LANCET
 
Episodes of adolescent mental disorder often precede mental disorders in young adults. However, many such disorders, especially when brief in duration, are limited to the teenage years, with further symptom remission common in the late 20s. The resolution of many adolescent disorders gives reason for optimism that interventions that shorten the duration of episodes could prevent much morbidity later in life.
 
THE NEW ENGLAND JOURNAL OF MEDICINE
 
Rates of diabetes-related complications have declined substantially in the past two decades, but a large burden of disease persists because of the continued increase in the prevalence of diabetes. (Funded by the Centers for Disease Control and Prevention.).
This blinded trial did not show a significant reduction of systolic blood pressure in patients with resistant hypertension 6 months after renal-artery denervation as compared with a sham control. (Funded by Medtronic; SYMPLICITY HTN-3 ClinicalTrials.gov number, NCT01418261.).
The adenoma detection rate was inversely associated with the risks of interval colorectal cancer, advanced-stage interval cancer, and fatal interval cancer. (Funded by the Kaiser Permanente Community Benefit program and the National Cancer Institute.).
The new ACC-AHA guidelines for the management of cholesterol would increase the number of adults who would be eligible for statin therapy by 12.8 million, with the increase seen mostly among older adults without cardiovascular disease. (Funded by the Duke Clinical Research Institute and others.).
Administration of aspirin before surgery and throughout the early postsurgical period had no significant effect on the rate of a composite of death or nonfatal myocardial infarction but increased the risk of major bleeding. (Funded by the Canadian Institutes of Health Research and others; POISE-2 ClinicalTrials.gov number, NCT01082874.).
In patients with heart failure and a preserved ejection fraction, treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure. (Funded by the National Heart, Lung, and Blood Institute; TOPCAT ClinicalTrials.gov number, NCT00094302.).
In asymptomatic persons at average risk for colorectal cancer, multitarget stool DNA testing detected significantly more cancers than did FIT but had more false positive results. (Funded by Exact Sciences; ClinicalTrials.gov number, NCT01397747.).
Among patients in our study, an elevated risk of thrombosis persisted until at least 12 weeks after delivery. However, the absolute increase in risk beyond 6 weeks after delivery was low. (Funded by the National Institute of Neurological Disorders and Stroke.).
 
THORAX
 
Regular dispensation of ICS+LABA was not associated with an increased risk of asthma-related hospitalisation compared with regular dispensation of ICS alone. Adherence to ICS in patients who regularly receive ICS+LABA seems to be an important factor in the prevention of adverse asthma-related outcomes.
 
Última actualización el Miércoles, 18 de Junio de 2014 16:22
 

                      

XXVIII Congreso de Comunicación y Salud

 

 

semFYC - JRT 2017

 

Cáceres, 10 y 11 de Noviembre 2017


____________________________

 Para pacientes
@pontealdiaAP
 @pontealdiaURG
55 e.SAMFyC

 


 

semFYC
 

 

Estadisticas

Ver contenido por hits : 1101555



La SAMFyC:
 C/ Arriola, 4, bajo D, CP.18001 - Granada. Email: samfyc@samfyc.es; Teléfono: 958 804 201 - Fax: 958 804 202. Horario de invierno: lunes a jueves de 9:00 a 17:30 horas; viernes de 9:00 a 14:30 horas. Horario de verano: lunes a viernes de 8:00 a 15:00h. Todos los derechos reservados. Aviso Legal. 


¡CSS Válido!

Diseño web